Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a form of folate needed for DNA, RNA and protein synthesis. By depleting these building blocks, it halts the proliferation of rapidly dividing cells such as cancerous lymphocytes and overactive immune cells.

The specific dose of Methotrexate Accord is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and treatment protocol. Dosage regimens vary widely across indications and are individualized for safety and efficacy.

Methotrexate Accord is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Methotrexate is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Methotrexate’s broad activity against both malignant and autoimmune cells makes it useful across oncology and rheumatology, while some alternatives may be more disease‑specific or have different toxicity profiles.

Methotrexate Accord should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken, and it should remain in its original packaging until ready for use to maintain stability.

Methotrexate Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intrathecal routes, depending on the clinical indication and prescribing physician’s protocol. Administration is performed by qualified healthcare professionals in a controlled setting.

The most serious risks include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis or interstitial pneumonitis, and renal impairment. Patients should be monitored regularly with laboratory tests and clinical assessments to detect these complications early.

Methotrexate Accord is contraindicated in pregnant women, individuals with severe hepatic or renal dysfunction, patients with known hypersensitivity to methotrexate or its excipients, and those receiving live vaccines. Caution is also advised for patients with active infections or immunodeficiency.